Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Nagoya University Establish Bio Venture Company To Develop Arteriosclerosis Drugs

This article was originally published in PharmAsia News

Executive Summary

Nagoya City University established the venture company Hyks Laboratories to develop drugs to treat and prevent arteriosclerosis. Utilizing funds from the Japan Science and Technology Agency, the university's school of medicine has been focusing on research and development of a drug to increase blood's high-density lipoproteins count, Based on the research results, the company also plans to partner with pharmaceutical companies to conduct basic research on HDL functions. Cerebral vascular diseases account for one third of the total deaths in Japan and prevention and treatment have become a major topic for medical researchers and pharmaceutical companies. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts